Cirmtuzumab
Monoclonal antibody
- Investigational
- 1643432-38-5 Y
- FEH7RQ7B3J
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
References
- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Blood. 126 (23): 1736. doi:10.1182/blood.V126.23.1736.1736.
- ^ "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e